Genmab launches new case against Janssen, demands compensation and royalties

Despite recently losing a court case against US-based Janssen concerning milestone payments for cancer drug Darzalex Faspro, the Danish firm is now initiating new arbitration.
Photo: Genmab/PR
Photo: Genmab/PR
by marketwire, translated by catherine brett

Danish biotech firm Genmab has commenced new arbitration against its US-based partner Janssen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading